李氏大药厂(00950)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00950 李氏大药厂

已收盘 07-27 15:56:27

1.130

-0.030

-2.59%

最高1.170	最低1.130	成交量24.70万
今开1.160	昨收1.160	日振幅3.45%
总市值6.66亿	流通市值6.65亿	总股本5.89亿
成交额28.41万	换手率0.04%	流通股本5.89亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00950","market":"HK","secType":"STK","nameCN":"李氏大药厂","latestPrice":1.13,"timestamp":1785138987014,"preClose":1.16,"halted":0,"volume":247000,"delay":0,"changeRate":-0.025862068965517265,"floatShares":588835343,"shares":589000000,"eps":0.1561,"marketStatus":"已收盘","change":-0.03,"latestTime":"07-27 15:56:27","open":1.16,"high":1.17,"low":1.13,"amount":284115,"amplitude":0.034483,"askPrice":1.16,"askSize":179000,"bidPrice":1.13,"bidSize":12000,"shortable":0,"etf":0,"ttmEps":0.1561,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785202200000},"marketStatusCode":5,"adr":0,"listingDate":1026662400000,"exchange":"SEHK","adjPreClose":1.16,"dividendRate":0.039823,"openAndCloseTimeList":[[1785115800000,1785124800000],[1785128400000,1785139200000]],"volumeRatio":0.531183,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00950","defaultTab":"news","newsList":[{"id":"1145304953","title":"艾士林制药签署协议，获得特定药品独家开发与商业化权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1145304953","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145304953?lang=zh_cn&edition=full","pubTime":"2026-07-21 19:03","pubTimestamp":1784631821,"startTime":"0","endTime":"0","summary":"艾士林制药公司近日宣布，已成功签署一项重要协议，从而获得了特定药物产品在全球范围内的独家开发与商业化权利。此举标志着该公司在拓展其产品管线与强化市场竞争力方面迈出了关键一步。\n根据协议条款，艾士林将全权负责这些药物的后续研发、临床试验推进以及最终的上市推广。此项合作有望为公司在未来数年内带来新的增长动力，并巩固其在相关治疗领域的战略布局。公司管理层表示，该协议符合其长期发展战略，旨在通过引入创新疗法来满足未竟的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652028501","title":"李氏大药厂(00950)就干扰素ALPHA-2B产品与ASHLINS订立大中华地区以外独家许可及供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2652028501","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652028501?lang=zh_cn&edition=full","pubTime":"2026-07-17 21:36","pubTimestamp":1784295413,"startTime":"0","endTime":"0","summary":"智通财经APP讯，李氏大药厂 发布公告，于2026年7月6日，公司与Ashlins Ocular Pharmaceuticals, Inc. 订立独家许可协议。根据该协议，公司同意向Ashlins许可及供应干扰素Alpha-2b，以供其于中国内地、香港、澳门及台湾以外所有地区开发及商业化用于诊断、预防或治疗若干人类疾病的药品。干扰素Alpha-2b乃一种透过重组DNA技术生产的重组人I型干扰素活性药物成分，用作具有抗病毒及免疫调节活性的药品的活性物质。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1583","06622","BK1574","00950","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136516681","title":"李氏大药厂（00950）签署干扰素Alpha-2b大中华区以外独家许可及供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1136516681","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136516681?lang=zh_cn&edition=full","pubTime":"2026-07-17 21:35","pubTimestamp":1784295331,"startTime":"0","endTime":"0","summary":"2026年7月17日，李氏大药厂控股有限公司发布自愿性公告称，公司已于2026年7月6日与美国生物医药公司Ashlins Ocular Pharmaceuticals, Inc.订立独家许可协议。根据协议，李氏大药厂将向Ashlins许可并供应干扰素Alpha-2b，用于在中国内地、香港、澳门及台湾以外地区开发及商业化针对若干人类疾病的药品。干扰素Alpha-2b是一种通过重组DNA技术生产的重组人I型干扰素活性药物成分，具有抗病毒及免疫调节活性。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147251721","title":"李氏大药厂与Ashlins Ocular达成独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1147251721","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147251721?lang=zh_cn&edition=full","pubTime":"2026-07-17 21:34","pubTimestamp":1784295263,"startTime":"0","endTime":"0","summary":"李氏大药厂于7月6日宣布，已与Ashlins Ocular Pharmaceuticals签署一项独家许可协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140684250","title":"李氏大药厂更新6月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1140684250","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140684250?lang=zh_cn&edition=full","pubTime":"2026-07-02 16:56","pubTimestamp":1782982582,"startTime":"0","endTime":"0","summary":"李氏大药厂控股有限公司于2026年7月2日发布截至2026年6月30日的股份变动月报表。报告显示，公司在2026年6月期间注册股本与已发行股份数均保持不变。报告期初和期末已发行股份数量均为588,835,343股，库藏股数量为0股，说明公司期间未进行任何新增发行、股份购回或注销活动，股本结构保持稳定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643646750","title":"李氏大药厂(00950)拟回购不多于5000万港元公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2643646750","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643646750?lang=zh_cn&edition=full","pubTime":"2026-06-16 21:13","pubTimestamp":1781615596,"startTime":"0","endTime":"0","summary":"智通财经APP讯，李氏大药厂 发布公告，公司已决定透过行使公司股东于2026年5月21日举行的公司股东周年大会上授予董事会购回公司股份的一般授权，实行一项股份购回计划。根据购回授权，公司获准购回最多达于授出购回授权的相关决议案通过当日已发行股份总数10%的本身股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00950","06622","BK1583","BK1574","BK1587","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641100113","title":"【券商聚焦】国海证券：李氏大药厂(00950)战略收购催化价值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2641100113","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641100113?lang=zh_cn&edition=full","pubTime":"2026-06-08 17:10","pubTimestamp":1780909801,"startTime":"0","endTime":"0","summary":"关键催化事件：2025年12月，公司全资附属子公司NPI以1500万美元收购Alexza核心资产，获得Staccato One Breath Technology吸入给药技术平台及相关产品管线、知识产权和生产设施。公司连同NPI有望就Staccato阿普唑仑获得最高6050万美元的里程碑付款+分级特许权使用费。Staccato阿普唑仑用于癫痫发作的3期临床预计2026年读出主要终点。","market":"us","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983252","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0276","BK0188","BK1574","BK0028","00950","BK1583","BK1191","BK1587","BK0183","000750","BK0174","06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640909331","title":"董事总经理李烨妮增持李氏大药厂(00950)4.15万股 每股作价1.06港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640909331","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640909331?lang=zh_cn&edition=full","pubTime":"2026-06-03 19:08","pubTimestamp":1780484900,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，5月29日，董事总经理李烨妮增持李氏大药厂(00950)4.15万股，每股作价1.06港元，总金额约为4.4万港元。增持后最新持股数目约为1.28亿股，最新持股比例为21.77%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06622","EWH","BK1587","BK1574","BK1191","BK1583","00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640957411","title":"李氏大药厂(00950)：合成表面活化剂项目获批资金","url":"https://stock-news.laohu8.com/highlight/detail?id=2640957411","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640957411?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:07","pubTimestamp":1780322823,"startTime":"0","endTime":"0","summary":"智通财经APP讯，李氏大药厂(00950)发布公告，李氏大药厂将获得盖茨基金会的财务资金，以支持集团的合成表面活化剂项目。此获资助项目的短期目标为成功完成研究及开发活性药物成分(API)及制剂，以及该药物的制造过程。最终目标为以可负担的价格将此款救命药物引进中低收入国家，特别是为帮助患上呼吸窘迫症候群的早产婴儿。董事会认为，盖茨基金会提供的资金支持相当切合公司在儿科及罕见病领域的策略重点，彰显集团对提高全球获得医疗保健服务的机会的持续承诺，并运用其创新的药物递送平台满足关键的医疗需求缺口。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448780.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","06622","BK1574","BK1583","BK1191","00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136754306","title":"李氏大药厂5月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1136754306","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136754306?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:32","pubTimestamp":1780306324,"startTime":"0","endTime":"0","summary":"李氏大药厂于2026年6月1日发布截至2026年5月31日止的证券变动月报表，披露报告期内公司股本结构及股份变动等情况。根据公告，李氏大药厂的法定股本与已发行股本维持稳定。购回及注销方面，报告期内未发生任何购回、注销或库藏股变动。月报显示本月内无新授予、行使或失效的期权变动，上述购股权数量保持不变。公司在公告中表示，截至2026年5月末，符合香港联交所相关法规所规定的最低公眾持股量要求。本次公告由董事李小芳签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634280989","title":"李氏大药厂(00950)拟斥资2500万元参投生命健康产业基金 布局生物科技赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2634280989","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634280989?lang=zh_cn&edition=full","pubTime":"2026-05-11 22:26","pubTimestamp":1778509575,"startTime":"0","endTime":"0","summary":"李氏大药厂(00950)公布，于2026年5月11日，公司的间接全资附属公司兆科合肥、普通合伙人瑞伏博健及其他有限合伙人订立有限合伙协议，据此，该等合伙人向基金出资人民币2亿元，而兆科合肥同意向基金出资人民币2500万元，相当于约12.5%基金权益。基金的目的为寻求投资于生命与健康、生物科技及相关上下游行业的非上市实体，符合公司的业务策略，透过于医药领域的策略合伙、投资及收购加强业务。投资基金符合集团的核心策略，透过具影响力的合伙及收购扩大其医药及保健版图。借认购基金的有限合伙权益，该集团得以间接涉足生物科技及生命科学领域的非上市实体的高增长，善用普通合伙人深厚的行业知识。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440423.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["XBI","BK1587","BK4581","BK1583","BK1574","BK1191","00950","BK4588","159837","06622","BK4585","HBImain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186867226","title":"李氏大药厂旗下兆科合肥将于2026年5月11日向合伙企业注资2500万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186867226","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186867226?lang=zh_cn&edition=full","pubTime":"2026-05-11 22:21","pubTimestamp":1778509272,"startTime":"0","endTime":"0","summary":"李氏大药厂控股有限公司宣布，其附属公司兆科合肥将于2026年5月11日向一家合伙企业注资人民币2500万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122881517","title":"李氏大药厂4月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1122881517","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122881517?lang=zh_cn&edition=full","pubTime":"2026-05-04 21:56","pubTimestamp":1777902970,"startTime":"0","endTime":"0","summary":"李氏大药厂控股有限公司于2026年5月4日发布截至2026年4月30日的股份变动月报表。报告显示，公司本月无新增发行股份、购回、注销或库藏股变动，股本维持稳定。已发行股份数量亦维持在588,835,343股，库存股份数量仍为0股。公司确认，截至本月末，公众持股量已符合法定最低要求。公告中同时披露，公司严格遵守香港联交所《上市规则》及相关法律法规开展股份相关业务。本期月报由公司董事李小芳签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196572568","title":"李氏大药厂2025年度营收攀升至14.36亿港元 多元产品组合支撑稳健增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1196572568","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196572568?lang=zh_cn&edition=full","pubTime":"2026-04-23 18:12","pubTimestamp":1776939175,"startTime":"0","endTime":"0","summary":"李氏大药厂在截至2025年12月31日止年度实现收入14.36亿港元，较2024年度的13.99亿港元上升2.6%。期内本公司拥有人应占溢利为9,193.8万港元，同比下降1.2%，每股基本盈利15.61港仙。公司通过适度派息维持股东回报，全年股息合计与上一年相近。综合来看，李氏大药厂2025年度在收入和产品覆盖面上保持稳健增长，继续加大研发投入与国际布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"李氏大药厂2025年度营收攀升至14.36亿港元 多元产品组合支撑稳健增长","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149508148","title":"李氏大药厂3月股份变动月报：已发行股份保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1149508148","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149508148?lang=zh_cn&edition=full","pubTime":"2026-04-01 22:51","pubTimestamp":1775055070,"startTime":"0","endTime":"0","summary":"李氏大药厂控股有限公司于2026年4月1日发布截至2026年3月31日的股份变动月报。公告显示，公司于报告期内保持法定注册股本为1,000,000,000股，面值每股0.05港元，总额50,000,000港元，较上月无变化。公司公布的已发行股份数量与上月相同，均为588,835,343股，报告期内并无新增发行股份或购回、注销及库藏股活动。公告同时强调，公司在本月所有证券发行或库藏股转让中遵守相关上市规则、法律及监管规定，履行了相应审批程序。该月报由公司董事李小芳签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177257362","title":"李氏大药厂将于2026年06月15日派发末期股息每股0.023港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1177257362","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177257362?lang=zh_cn&edition=full","pubTime":"2026-03-30 18:12","pubTimestamp":1774865553,"startTime":"0","endTime":"0","summary":"李氏大药厂(00950)\n根据公司公告，董事会建议就截至2025年12月31日止年度派发末期股息，每股0.023港元，须于2026年5月21日经股东大会批准。该股息预期于2026年6月15日派发。\n公告显示，股份将于2026年5月27日除净。在2026年5月28日16时30分前递交过户文件，可于派息时获得相关股息。公司将于2026年5月29日至6月1日暂停办理股份过户登记，2026年6月1日为股息派发的记录日期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185029707","title":"李氏大药厂2025财年营收14.36亿港元，毛利率降至50.8%，研发投入显著增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1185029707","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185029707?lang=zh_cn&edition=full","pubTime":"2026-03-30 17:24","pubTimestamp":1774862665,"startTime":"0","endTime":"0","summary":"李氏大药厂于2025财年实现收入14.36亿港元，同比增加2.6%。毛利7.30亿港元，较上一年度下降3.2%，毛利率由53.8%降至50.8%。本公司拥有人应占纯利录得9194万港元，较2024财年的9310万港元轻微下降1.2%，基本及摊薄每股盈利均为15.61港仙。董事会建议派付末期股息每股普通股2.3港仙。销售及分销费用为3.34亿港元，占收入比率由27.7%降至23.3%。财务状况方面，截至2025年12月31日，集团总资产为34.64亿港元，流动资产11.69亿港元，包括3.50亿港元的现金及现金等值。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623318798","title":"李氏大药厂(00950)发布年度业绩 股东应占溢利9193.8万港元 同比减少1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623318798","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623318798?lang=zh_cn&edition=full","pubTime":"2026-03-30 17:19","pubTimestamp":1774862354,"startTime":"0","endTime":"0","summary":"智通财经APP讯，李氏大药厂(00950)发布截至2025年12月31日止年度业绩，集团收益14.36亿港元，同比增长2.6%;股东应占溢利9193.8万港元，同比减少1.2%;每股盈利15.61港仙;拟派末期股息每股2.3港仙。公告称，公司拥有人应占纯利减少反映严峻市场环境及研发支出增加的合并影响，抵销了收益增长及销售费用减少所带来的裨益，导致纯利同比下滑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1587","BK1583","00950","06622","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622071591","title":"李氏大药厂(00950)：茵若飒取得国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2622071591","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622071591?lang=zh_cn&edition=full","pubTime":"2026-03-25 21:37","pubTimestamp":1774445826,"startTime":"0","endTime":"0","summary":"智通财经APP讯，李氏大药厂(00950)发布公告，于2026年3月17日，中国国家药品监督管理局(国家药监局)已批准茵若飒(由Cosette Pharmaceuticals拥有并已授予李氏大药厂许可)用于治疗具有中重度症状(不包括泌尿系症状)的绝经后女性外阴阴道萎缩。继本公司全资附属公司兆科药业(合肥)有限公司进行的第III期、多中心、随机、双盲、平行对照临床试验成功完成后，是次获批标志着一个重要的里程碑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419040.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06622","BK1191","00950","BK1574","BK1587","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616535094","title":"李氏大药厂03月04日主力净流出47.4万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2616535094","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616535094?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:15","pubTimestamp":1772612117,"startTime":"0","endTime":"0","summary":"03月04日, 李氏大药厂股价跌0.75%，报收1.32元，成交金额208.7万元，换手率0.27%，振幅5.26%，量比1.54。李氏大药厂今日主力资金净流出47.4万元，上一交易日主力净流出0万元。该股近5个交易日下跌8.28%，主力资金累计净流出92.1万元；近20日主力资金累计净流出103.6万元，其中净流出天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304161557a44a5878&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304161557a44a5878&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1583","BK1587","00950","BK1191","06622"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.leespharm.com","stockEarnings":[{"period":"1week","weight":0.0943},{"period":"1month","weight":0.1154},{"period":"3month","weight":0.0311},{"period":"6month","weight":-0.2251},{"period":"1year","weight":-0.2363},{"period":"ytd","weight":-0.2199}],"compareEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":0.0662},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0668},{"period":"1year","weight":-0.0274},{"period":"ytd","weight":-0.026}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"李氏大药厂控股有限公司是一家主要从事药品开发、制造、市场推广及销售业务的投资控股公司。该公司通过两个分部运营业务。引进产品分部买卖引进的产品。其引进产品包括可益能注射液、菲普利口服溶液等。专利产品分部制造及销售自行研发的产品。其研发产品包括锐思力药片、ADASUVE吸入粉雾剂等。该公司药品覆盖心血管及传染疾病、皮肤医学、肿瘤学、妇科学及眼科学等领域。该公司主要在中国大陆、香港、台湾开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5625,"avgChangeRate":0.049747},{"month":2,"riseRate":0.375,"avgChangeRate":-0.02291},{"month":3,"riseRate":0.4375,"avgChangeRate":-0.02912},{"month":4,"riseRate":0.4375,"avgChangeRate":-0.000886},{"month":5,"riseRate":0.625,"avgChangeRate":0.036937},{"month":6,"riseRate":0.352941,"avgChangeRate":-0.025949},{"month":7,"riseRate":0.529412,"avgChangeRate":0.031743},{"month":8,"riseRate":0.375,"avgChangeRate":-0.037869},{"month":9,"riseRate":0.4375,"avgChangeRate":0.016064},{"month":10,"riseRate":0.4375,"avgChangeRate":-0.006834},{"month":11,"riseRate":0.5625,"avgChangeRate":0.012698},{"month":12,"riseRate":0.4375,"avgChangeRate":0.016854}],"exchange":"SEHK","name":"李氏大药厂","nameEN":"LEE'S PHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"李氏大药厂(00950)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供李氏大药厂(00950)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"李氏大药厂,00950,李氏大药厂股票,李氏大药厂股票老虎,李氏大药厂股票老虎国际,李氏大药厂行情,李氏大药厂股票行情,李氏大药厂股价,李氏大药厂股市,李氏大药厂股票价格,李氏大药厂股票交易,李氏大药厂股票购买,李氏大药厂股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"李氏大药厂(00950)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供李氏大药厂(00950)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}